ClinicalTrials.gg
CompletedNCT01177384Updated Aug 16, 2018Results posted

Clinical Trial to Evaluate the Safety and Efficacy of the Addition of Sitagliptin in Participants With Type 2 Diabetes Mellitus Receiving Acarbose Monotherapy (MK-0431-130)

A Phase 3 interventional study of Sitagliptin phosphate and Comparator: Placebo in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-16.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
380
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
46th of 197
380 · median 102
Started
2011
with 12 others
Phase 3
74 of 198
none open now
Registered
91st of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 46th largest by enrollment of the 197 interventional ones that give a count, is one of 13 that started in 2011, is one of 74 in phase 3, and was the 91st registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study will evaluate whether the addition of sitagliptin reduces hemoglobin A1C (A1C) more than the addition of placebo for participants with type 2 diabetes mellitus (T2DM) on a steady dose of acarbose. The primary hypothesis is that the addition of sitagliptin 100 mg once daily (q.d.) reduces A1C more than the addition of placebo in participants with T2DM with inadequate glycemic control on acarbose monotherapy.

Read the detailed description

The study includes an 8-week antihyperglycemic agent (AHA) wash-off period* (which includes a 2-week single-blind placebo run-in period) followed by a 24-week double-blind treatment period. All participants will receive open-label acarbose at a minimum dose of 50 mg three times daily (t.i.d.) during the run-in and treatment periods.

*: Wash-off only applicable to patients who were on acarbose and another AHA.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Type 2 diabetes mellitus
  • T2DM
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • has T2DM and is on acarbose alone at a stable dose of at least 50 mg t.i.d.(three times a day) for at least 10 weeks or on acarbose at a stable dose of at least 50 mg t.i.d. (three times a day) for at least 10 weeks in combination with another antihyperglycemic agent (AHA)
  • is at least 18 years of age (for participants in India: between 18 and 65 years of age)
  • male or female who is unlikely to conceive (not of , or agrees to remain abstinent or use [or have partner use] acceptable if of reproductive potential)

Exclusion criteria

Exclusion Criteria:

  • has a history of type 1 diabetes mellitus
  • use of thiazolidinedione (TZD), dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, or insulin
  • has the following cardiovascular disorders: acute coronary syndrome; new or worsening symptoms of coronary heart disease; coronary artery intervention; stroke or transient ischemic neurological disorder
  • has liver or kidney disease
  • has cancer or any disease or disorder as judged by the Investigator
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
380 participants (actual)

Study arms

  • Experimental
    Sitagliptin

    Sitagliptin 100 mg daily (q.d.) + acarbose (continuing the current stable dose of at least 50 mg three times daily \[t.i.d.\])

    Drug: Sitagliptin phosphate · Drug: Acarbose · Drug: Glimepiride

  • Placebo comparator
    Placebo

    Placebo q.d. + acarbose (continuing the current stable dose of at least 50 mg t.i.d.)

    Drug: Comparator: Placebo · Drug: Acarbose · Drug: Glimepiride

Interventions

  • Sitagliptin, 100 mg tablet once daily, orally for 24 weeks

    Also known as: Januvia

  • DrugComparator: Placebo

    Placebo, to match sitagliptin tablet, once daily, orally for 24 weeks

  • Acarbose 50 mg or 100 mg tablet, 3 times daily, orally (continuing on the stable dose established prior to screening) for 24 weeks

    Also known as: Precose

  • Participants not meeting specific glycemic goals during the study will use glimepiride as rescue therapy. For countries where glimepiride is not available, participants will receive a sulfonylurea marketed in that country as rescue therapy.

    Also known as: Amaryl®, Glimy

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Hemoglobin A1c (A1C) at Week 24

    A1C is measured as a percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent. Efficacy analyses treated data as missing after the initiation of rescue therapy.

    Time frame: Baseline and Week 24

  2. Number of Participants Who Experienced at Least One Adverse Event

    Time frame: Up to Week 24 + 14 Day Post-Study Follow-up

  3. Number of Participants Who Discontinued Study Drug Due to an Adverse Event

    Time frame: Up to 24 Weeks

Secondary outcomes

  1. Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24

    Change from baseline at Week 24 is defined as Week 24 FPG minus Week 0 FPG. Efficacy analyses treated data as missing after the initiation of rescue therapy.

    Time frame: Baseline and Week 24

07

Results

Posted Apr 28, 2014

Participant flow

Participant flow — Overall Study
MilestoneSitagliptinPlacebo
Started191190
Completed177164
Not completed1426
Withdrew: Adverse event64
Withdrew: Lack of efficacy01
Withdrew: Lost to follow-up34
Withdrew: Physician decision03
Withdrew: Protocol violation02
Withdrew: Withdrawal by subject512

Outcome measures

PrimaryChange From Baseline in Hemoglobin A1c (A1C) at Week 24

A1C is measured as a percent. Thus, this change from baseline reflects the Week 24 A1C percent minus the Week 0 A1C percent. Efficacy analyses treated data as missing after the initiation of rescue therapy.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · Percent
Change From Baseline in Hemoglobin A1c (A1C) at Week 24
PercentSitagliptinPlacebo
Change From Baseline in Hemoglobin A1c (A1C) at Week 24-0.76 (-0.93 to -0.59)-0.14 (-0.32 to 0.03)
Statistical analysis
  • Sitagliptin vs Placebo · ANCOVA · p = <.001 (The ANCOVA model included terms for treatment and prior antihyperglycemic agent (AHA) therapy status (on acarbose monotherapy, or on acarbose in combination with other AHA(s)) and a covariate for baseline A1C.) · Difference in least squares mean: -0.62 · 95% CI -0.79 to -0.44
SecondaryChange From Baseline in Fasting Plasma Glucose (FPG) at Week 24

Change from baseline at Week 24 is defined as Week 24 FPG minus Week 0 FPG. Efficacy analyses treated data as missing after the initiation of rescue therapy.

Time frame:
Baseline and Week 24
Reported as:
Least squares mean · mg/dL
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
mg/dLSitagliptinPlacebo
Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24-17.9 (-25.3 to -10.5)-3.5 (-11.1 to 4.1)
Statistical analysis
  • Sitagliptin vs Placebo · ANCOVA · p = <.001 (The ANCOVA model included terms for treatment and prior AHA therapy status (on acarbose monotherapy, or on acarbose in combination with other AHA(s)) and a covariate for baseline FPG.) · Difference in least squares mean: -14.4 · 95% CI -21.8 to -7.0
PrimaryNumber of Participants Who Experienced at Least One Adverse Event
Time frame:
Up to Week 24 + 14 Day Post-Study Follow-up
Reported as:
Number · Participants
Number of Participants Who Experienced at Least One Adverse Event
ParticipantsSitagliptinPlacebo
Number of Participants Who Experienced at Least One Adverse Event6258
PrimaryNumber of Participants Who Discontinued Study Drug Due to an Adverse Event
Time frame:
Up to 24 Weeks
Reported as:
Number · Participants
Number of Participants Who Discontinued Study Drug Due to an Adverse Event
ParticipantsSitagliptinPlacebo
Number of Participants Who Discontinued Study Drug Due to an Adverse Event52

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin—10/191 (5.2%)0/191 (0%)
Placebo—1/189 (0.5%)0/189 (0%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventSitagliptinPlacebo
CholecystitisHepatobiliary disorders2/1910/189
Invasive ductal breast carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1911/189
Cardia flutterCardiac disorders1/1910/189
Pancreatitis chronicGastrointestinal disorders1/1910/189
Bile duct stoneHepatobiliary disorders1/1910/189
GastroenteritisInfections and infestations1/1910/189
ThymomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1910/189
Cerebral infarctionNervous system disorders1/1910/189
Transient ischaemic attackNervous system disorders1/1910/189
Calculus urinaryRenal and urinary disorders1/1910/189

Baseline characteristics

All participants randomized population. The baseline characteristics module does not include the second sequential randomization of a participant in the placebo group. Data for the second sequential randomization were excluded from the efficacy and safety analyses.

Age, Continuous
Age, Continuous(Years)SitagliptinPlaceboTotal
Mean56.5 ± 8.957.8 ± 9.557.1 ± 9.2
Sex: Female, Male
Sex: Female, Male(Participants)SitagliptinPlaceboTotal
Female9492186
Male9797194
Hemoglobin A1c (A1C)
Hemoglobin A1c (A1C)(Percent)SitagliptinPlaceboTotal
Mean8.09 ± 0.798.08 ± 0.908.08 ± 0.85
Fasting plasma glucose
Fasting plasma glucose(mg/dL)SitagliptinPlaceboTotal
Mean177.3 ± 37.5177.5 ± 40.2177.4 ± 38.8
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Wang W, Ning G, Ma J, Liu X, Zheng S, Wu F, Xu L, O'Neill EA, Fujita KP, Engel SS, Kaufman KD, Shankar RR. A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone. Curr Med Res Opin. 2017 Apr;33(4):693-699. doi: 10.1080/03007995.2016.1277200. Epub 2017 Jan 25. PubMed 28035868 ↗

Individual participant data

Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2011 to primary completion in Mar 2013, 26 months.

Results were first posted in Apr 2014, 1 year 1 month after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 26 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2010
First posted
Aug 9, 2010
StartActual
Jan 25, 2011
Primary completionActual
Mar 25, 2013
CompletionActual
Mar 25, 2013
Results first posted
Apr 28, 2014
Last update
Aug 16, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01177384
Responsible party
Sponsor
First posted
Aug 9, 2010
Start date
Jan 25, 2011
Primary completion
Mar 25, 2013
Completion
Mar 25, 2013
Results posted
Apr 28, 2014
Last update
Aug 16, 2018

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion